NVO - Novo Nordisk A/S

NYSE - Nasdaq Real Time Price. Currency in USD
50.56
-0.12 (-0.24%)
As of 1:54PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close50.13
Open50.68
Bid50.56 x 700
Ask50.57 x 300
Day's Range50.37 - 50.68
52 Week Range30.89 - 50.95
Volume609,175
Avg. Volume2,017,396
Market Cap123.09B
Beta0.51
PE Ratio (TTM)20.85
EPS (TTM)2.42
Earnings DateN/A
Forward Dividend & Yield0.95 (1.93%)
Ex-Dividend Date2017-08-17
1y Target Est50.20
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling
    Zacks5 hours ago

    Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

    Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.

  • Reutersyesterday

    Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

    WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.

  • Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide
    PR Newswire2 days ago

    Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide

    PLAINSBORO, N.J., Oct. 18, 2017 /PRNewswire/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes. Based on the data contained in the New Drug Application (NDA) for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to demonstrate the efficacy and safety profile of semaglutide for the treatment of type 2 diabetes in adults.

  • Reuters2 days ago

    U.S. FDA panel backs approval of Novo Nordisk diabetes drug

    Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Novo Nordisk is hoping that semaglutide, administered through a once-weekly injection, will take market share from Eli Lilly & Co's once-weekly Trulicity, which in turn has been taking share from Novo Nordisk's once-daily Victoza.

  • Impax Laboratories and Amneal Pharmaceuticals Agree to Merge
    Zacks2 days ago

    Impax Laboratories and Amneal Pharmaceuticals Agree to Merge

    Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.

  • Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
    Zacks2 days ago

    Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

    Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

  • Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
    Zacks3 days ago

    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

  • Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
    Zacks3 days ago

    Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

    Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

  • Immune Design's Sarcoma Candidate to Enter Phase III in 2018
    Zacks3 days ago

    Immune Design's Sarcoma Candidate to Enter Phase III in 2018

    Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks4 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • Reuters4 days ago

    Novo Nordisk diabetes drug effective, preliminary FDA review finds

    Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday. The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of advisors to the agency who will discuss the drug, semaglutide, and recommend whether it should be approved. The FDA typically follows the recommendations of its advisors.

  • Why Should You Invest in Novo Nordisk (NVO) Stock Right Now
    Zacks10 days ago

    Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

  • Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal
    Zacks14 days ago

    Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal

    The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.

  • PR Newswire17 days ago

    Striking Blood Sugar Balance is Critical for Canadians Living with Diabetes

    New long-acting basal insulin now available to help adults living with type 1 and type 2 diabetes manage blood sugar levels MISSISSAUGA, ON , Oct. 3, 2017 /CNW/ - Today, Novo Nordisk announced the availability ...

  • Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
    Zacks18 days ago

    Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults

    Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.

  • Why MannKind Corporation Popped Today
    Motley Fool18 days ago

    Why MannKind Corporation Popped Today

    Traders cheer after management provided investors with a series of positive updates.

  • GlobeNewswire18 days ago

    Status regarding Novo Nordisk's holding of its own shares (30 September 2017)

    Bagsværd, Denmark, 2 October 2017 - In continuation of the company`s announcements dated 3 May 2017 and 9 August 2017 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the ...

  • Reuters21 days ago

    U.S. FDA approves Novo Nordisk fast-acting insulin Fiasp

    The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes. The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. Fiasp, or faster acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co's Humalog and Novo Nordisk's own NovoLog, known as NovoRapid outside the United States.

  • Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin
    PR Newswire21 days ago

    Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin

    PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp® (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.1 Fiasp® can be dosed at the beginning of a meal or within 20 minutes after starting a meal. The result of this has led to many people with diabetes not achieving their target A1C.

  • Orexigen's (OREX) Contrave Sales Improving on Promotions
    Zacks22 days ago

    Orexigen's (OREX) Contrave Sales Improving on Promotions

    Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

  • Working Mother names Novo Nordisk one of its "100 Best Companies"
    PR Newswire24 days ago

    Working Mother names Novo Nordisk one of its "100 Best Companies"

    PLAINSBORO, N.J., Sept. 26, 2017 /PRNewswire/ -- Novo Nordisk in the U.S. has been named to the "Working Mother 100 Best Companies" list which recognizes companies for their strong leadership in creating progressive workforce programs regarding advancement of women, flexibility, childcare and paid parental leave. The list is based on employee assessments. Earlier in this year, Novo Nordisk was recognized for the ninth consecutive year as a "Best Company to Work For" by Great Place to Work® and Fortune. "This year's winning companies know the value of keeping their employee moms engaged and supported," says Subha Barry, senior vice president & managing director of Working Mother Media.

  • Market Realist28 days ago

    A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17

    In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.

  • Market Realist29 days ago

    How Is Novo Nordisk’s Victoza Positioned after 2Q17?

    In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.

  • Market Realist29 days ago

    Xultophy Could Substantially Boost Novo Nordisk’s Revenue Growth

    In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.

  • Market Realist29 days ago

    An Update on Novo Nordisk’s Modern Insulin after 1H17

    In the first half of 2017, Novo Nordisk’s (NVO) NovoRapid generated revenues of DKK (Danish kroner) 10.4 billion, which reflected a 9.0% rise on a YoY (year-over-year) basis.